Merck & Co. Stock Holds Despite Wall Street Zen Downgrade

Merck & Co. stock has maintained its value despite being downgraded to 'Hold' by Wall Street Zen, according to MarketBeat.

The pharmaceutical company's stock price stood at $143.93 on September 12, 2026, with a market capitalization of $355 billion.

Wall Street Zen's rating change did not affect the overall consensus, which remains 'Moderate Buy' with an average target price of $151.32 per share.

Merck & Co.'s second-quarter results showed revenue of $16.61 billion and EPS of -$0.13, beating consensus estimates by $0.13 per share.